Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.65    0.10 (2.20%)
Bid:
4.65
Ask:
4.70
Spread: 0.05 (1.075%)
Market Cap: £223.18m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

AGM Statement

27 Nov 2012 07:01

RNS Number : 0347S
Seeing Machines Limited
27 November 2012
 



 

Seeing Machines Limited

("Seeing Machines" or the "Company")

 

AGM Statement

 

Seeing Machines, the AIM-listed technology company with a focus on vision based human machine interfaces, will tomorrow hold its Annual General Meeting in Canberra, Australia at the Clifton Suites on Northbourne, 100 Northbourne Ave, Canberra ACT 2601, at 5.00pm AEDT.

 

The Chairman, Terry Winters, will provide the following statement at the meeting:

"The Directors believe that the combination of eye and gaze tracking with facial interpretation will be at the core of future waves of technology and applications in computing and entertainment. We believe this will provide significant opportunities, as well as challenges, for Seeing Machines in the future as we increase our R&D effort to achieve a market leading capability.

 

"Seeing Machines also continues to win new business, most significantly within the Driver Safety Solution (DSS) business. This represents a significant vote of confidence in the capabilities of our revamped sales force and refocused products."

 

Commenting on these latest developments, Chief Executive Officer, Ken Kroeger, will make the following remarks:

"DSS has been specifically designed for deployment into fleets and environments where fatigue and operator distraction pose substantial risk to personnel and equipment. We anticipate sales of DSS will grow over the next 18 months as pressure on companies to monitor and manage these risks intensifies.

 

"As well as selling the DSS units, we derive revenue from recurring maintenance, support services and specialist fatigue management consulting, data management, analysis and reporting services. A particular focus for us going forward will be on growing our services income through the DSSi management reporting suite. We see this as a way to enhance our client relationships and improve the quality of earnings, revenue visibility and gross margins."

 

Closing the meeting, Terry Winters will conclude:

"I am pleased to report that in line with the statement made with the preliminary results in September, the first few months of the current financial year commencing 1 July 2012 have shown further strengthening of the Company's sales pipeline. I am therefore very pleased to report the Board is confident in the outlook for the current financial year and beyond."

 

A copy of the slide presentation to made at the Annual General Meeting will be made available on the Company's website: www.seeingmachines.com

 

Enquiries:

 

Seeing Machines Limited

Terry Winters (Chairman)

Ken Kroeger (Managing Director & CEO)

 

+61 (0) 411 411 111

+61 (2) 6103 4700

 

finnCap Ltd

 

Ed Frisby/Ben Thompson (Corporate Finance)

Simon Starr (Corporate Broking)

+44 (0) 20 7220 0500

Walbrook PR Ltd

Helen Westaway (Media Enquiries)Paul Cornelius (Investor Enquiries)

+44 (0) 20 7933 8780

 

 

About Seeing Machines Limited

Seeing Machines is a world leader in the development of premier products and applications that rely on capturing and understanding the behaviour of human faces and eyes. More information is available from our web site: www.seeingmachines.com

About Seeing Machines' Driver Safety Solution (DSS)

The Seeing Machines DSS suite is a rugged, non-invasive platform that uses cutting edge face and eye tracking techniques to deliver information on operator fatigue and distraction. The DSS has been specifically designed for deployment into fleets and environments where fatigue and operator distraction pose substantial risk to personnel and equipment and therefore need to be monitored and managed.

For more information on DSS, go to http://www.seeingmachines.com/product/dss/

About Seeing Machines' Fatigue Management Consulting

Seeing Machines supports its DSS technology with professional and scientific fatigue management consulting and training services designed to build understanding of how businesses can reduce the risk of operator fatigue and support the readiness, implementation and acceptance of its products. Seeing Machines has developed a comprehensive fatigue management framework through combined collaboration with leading fatigue research institutions and hands on experience in the field with organisations who proactively manage fatigue. Seeing Machines also provides detailed fatigue management training for site personnel to better enable them to understand the causes of, and manage their own fatigue. For more information on fatigue management, go to http://www.seeingmachines.com/fatigue-consultancy/

 

About Seeing Machines' faceAPI®

faceAPI® allows users to incorporate Seeing Machines world-class face tracking technology into their own products or applications. faceAPI provides a growing suite of image-processing modules created specifically for tracking and understanding faces and facial features. These powerful tracking modules are combined into a complete API toolkit that delivers a rich stream of information that can be incorporated into our customers' own products or services. Seeing Machines faceAPI® delivers a comprehensive, integrated solution for developing products that leverage real-time face tracking. All image-processing for face tracking is handled internally, removing the need for computer vision experience. For more information on faceAPI®, go to http://www.seeingmachines.com/product/faceapi/

About Seeing Machines' faceLAB®5

Seeing Machines has been creating advanced eye tracking algorithms since the company was founded in 2000. faceLAB®5 is the organisation's eye tracking system that allows researchers to objectively measure human behavior in a wide range of operational conditions and research settings. faceLAB®'s unique eye and facial tracking solution offers users rare flexibility, portability, and accuracy. For more information on faceLAB®, go to http://www.seeingmachines.com/product/facelab/

About Seeing Machines' Truefield® Analyzer (TFA)

Currently going through its final clinical trials, the TFA will make objective visual field testing a clinical reality. It combines objectivity with 'non-contact' ease of use, making it easy for technicians and patients, giving clinicians objectivity when assessing their patients' conditions. Assessing both eyes concurrently, TFA tests are fast and can be run in both full-test and screening modes. The tests' bilateral concurrency allows the consensual light reflex to be exploited to identify bilateral asymmetries improving test accuracy. Most importantly, the TFA makes objective perimetry a clinical reality. For more information on TFA, go to http://www.seeingmachines.com/product/truefield/

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMBKADDABDDBDB
Date   Source Headline
12th May 20267:00 amRNSUS$3.8m Order for Guardian BdMS
6th May 20267:00 amRNSQ3 FY2026 Quarterly KPIs
20th Apr 202612:30 pmRNSHolding(s) in Company
10th Apr 20268:53 amRNSStatement re alleged cyber threat
27th Mar 20267:00 amRNSHalf-year Financial Report
24th Feb 20267:00 amRNS-RPublication of Investor Presentation
18th Feb 20267:00 amRNSTrading Update - H1 FY2026
13th Feb 20267:30 amRNSAppointment of Joint Broker
11th Feb 20267:00 amRNSQ2 FY2026 Quarterly KPIs
13th Jan 202612:00 pmRNS-R3D Cabin Perception Mapping breaks new ground
6th Jan 20267:00 amRNSAgreement
5th Jan 20267:00 amRNS-R3D Cabin Perception Mapping to be unveiled at CES
5th Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNS-RSeeing Machines Announces Future Mobility Group
2nd Jan 20267:00 amRNS-RSeeing Machines Announces Future Mobility Group
17th Dec 20257:00 amRNS-RTechnical Paper Series - Intoxication launched
4th Dec 20257:00 amRNS-RSeeing Machines 2025 Guardian Insights Report
27th Nov 20257:00 amRNSResults of AGM
26th Nov 20257:30 amRNSJapanese Auto Award and Extended European Program
12th Nov 20257:05 amRNSQ1 FY2026 Quarterly KPIs
12th Nov 20257:00 amRNSGuardian order from US-based multinational company
6th Nov 20257:05 amRNS-RCollaboration with Magna milestone in China
3rd Nov 20257:00 amRNSBoard Changes
3rd Nov 20257:00 amRNSNotice of Annual General Meeting
30th Oct 20257:00 amRNSLATAM Distributor Orders 1,300 Guardian Units
29th Oct 20257:00 amRNSAdvanced Development Project with Japanese OEM
8th Oct 20257:00 amRNSUS$1.8m expansion order for Guardian BdMS
26th Sep 20257:00 amRNSExpanding Guardian prospects across Europe
25th Sep 20257:00 amRNSFY2025 Results and Annual Financial Report
24th Sep 20257:20 amRNSFirst Guardian contract through Mitsubishi
10th Sep 20257:05 amRNS-RSeeing Machines Launches Impairment Capability
10th Sep 20257:00 amRNSNotice of Results and Presentation
29th Aug 202510:10 amRNSDirector Dealing
21st Aug 20257:00 amRNSFY2025 Trading Update
5th Aug 20257:00 amRNSQ4 FY2025 Quarterly KPIs
30th Jun 20257:00 amRNSMitsubishi Electric Europe Guardian collaboration
27th Jun 20257:00 amRNSUS Guardian Gen 3 trial with Mitsubishi Electric
16th Jun 20258:59 amRNS$1.2 Million Agreement with Global Auto Leader
9th May 20252:31 pmRNSDirector dealing
1st May 20257:00 amRNSQ3 FY2025 Quarterly KPIs
29th Apr 20259:58 amRNSNotification of Major Holdings
8th Apr 20258:53 amRNSHoldings in Company
8th Apr 20257:00 amRNSDirector/PDMR Shareholding
4th Apr 20257:00 amRNSDirector dealing
2nd Apr 202511:00 amRNSLondon presentation for investors and analysts
2nd Apr 20257:00 amRNSDirector dealing
2nd Apr 20257:00 amRNSDirector dealing
1st Apr 202512:00 pmRNS-RSeeing Machines Announces 3D Camera Technology
31st Mar 20257:00 amRNSDirector/PDMR Shareholding
28th Mar 20257:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.